Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

3.500
-0.030-0.85%
Volume:392.50K
Turnover:1.36M
Market Cap:2.40B
PE:-7.87
High:3.530
Open:3.530
Low:3.365
Close:3.530
52wk High:6.790
52wk Low:2.760
Shares:687.00M
HK Float Shares:687.00M
Volume Ratio:0.71
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.445
ROE:6.39%
ROA:7.18%
PB:2.25
PE(LYR):-7.87
PS:3.63

Loading ...

Antengene-B Surges Over 9% as Pivotal Phase III CLINCH-3 Trial Completes First Patient Dosing

Stock News
·
Sep 21

Antengene Doses First Patient in Phase III Clinch-3 Trial of ATG-022 for Cldn18.2+ Gastric, GEJ Cancer

Reuters
·
Sep 21

Antengene Announces First Patient Dosed in Pivotal Phase Iii Clinch-3 Study of Atg-022

THOMSON REUTERS
·
Sep 21

ANTENGENE-B: THE CORE TRUST COMPANY LIMITED Acquires Shares, Long Position Rises to 10.84%

HK Disclosure
·
Sep 17

ANTENGENE-B: TCT (BVI) Limited Acquires Shares, Long Position Rises to 10.84%

HK Disclosure
·
Sep 17

ANTENGENE-B: Sheng Tang Acquires Shares via Off-Exchange Derivatives, Long Position Rises to 0.07%

HK Disclosure
·
Sep 16

ANTENGENE-B: Rafael Fonseca Acquires, Long Position Rises to 0.05%

HK Disclosure
·
Sep 16

ANTENGENE-B: Jing Qian Acquires, Long Position Rises to 0.07%

HK Disclosure
·
Sep 16

Antengene Publishes Preclinical Study of ATG-037 Plus Selinexor in Multiple Myeloma in Cancer Gene Therapy

Reuters
·
Sep 14

Antengene-B Grants 11.52 Million RSUs to 75 Participants under 2022 Scheme

Bulletin Express
·
Sep 10

Antengene Caps August With Unchanged Share Count, Confirms Adequate Public Float

Bulletin Express
·
Sep 03

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS
·
Aug 25

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News
·
Aug 25

Antengene Receives Australian HREC Green Light for Phase I “ATTRACT” Trial of Bispecific Antibody ATG-201

Bulletin Express
·
Aug 25

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Reuters
·
Aug 25

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS
·
Aug 25

China's InnoCare Pharma H1 Revenue Surges, Partly on Orelabrutinib Growth

Reuters
·
Aug 24

Press Release: Antengene Announces 2026 Interim Results: Achieves First

Dow Jones
·
Aug 24

Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms

Simply Wall St.
·
Aug 23

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Reuters
·
Aug 22